Shots:

• The companies collaborate with the Yangtze to commercialize eight biosimilars in China. The initial pipeline contains biosimilar candidates for the treatment of autoimmunity- ophthalmology- and oncology
• Alvotech and Alvotech & CCHT will be jointly responsible for the development- registration- and supply of biosimilars in China while Yangtze River Pharmaceutical will exclusively commercialize the biosimilars
• The manufacturing of biosimilars will be made in a new state-of-the-art biopharmaceutical facility- currently being built in Changchun- China- through the Alvotech & CCHT. The first phase of the facility is expected to be completed in 2021

­ Ref: Alvotech | Image: Alvotech